Immunocore Holdings (IMCR) stock

Melanoma treatment , market cap $1.5B

Melanoma treatment

Worth $1.5B

$32.38

+2.05%

As of Tuesday's close · Live for Pro members at the open

Quality Score

Below Average

In its industry

#115of 281

Biotech

Checks firing

3of 14

Choppy

From 52-week high

-20.5%

under its best in a year

IMCR's Quality Score rose 2 points on Tue, Nov 10, to 2. Its price climbed back above its average of the last 200 days and its price is now lower than a year ago.

Follow IMCR's trial news. Pro members can get an alert when Immunocore Holdings files news, and see its trials, share raises, and its CEO's filings.

Get an alert when IMCR files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next2026“…brenetafusp from the ovarian and lung cohorts in the Phase 1/2 trial at a medical conference later this year…”Trial data · SEC filing · Nov 6

Cash$901M in cash. One of the last four quarters brought cash in while the others used it.On Sep 30

Why is IMCR up?

Up 14% from Nov 5 to Nov 10.

Immunocore rose 14% from Nov 5 to Nov 10. 9 points of it came on Nov 6, the day of its results. Immunocore's Nov 6 release said: "The increase in net product sales was due to continued growth in the United States, Europe and international regions."

Sources: Price history, Nov 10, 2026; SEC filing, Nov 6, 2026; Company release, Nov 6, 2026

1 more reason, free with an account →1 more reason why IMCR rose 14% since Nov 5, from its filings, with the other side, the company's words, the timeline, and its peers, for Pro members.

Why IMCR still lags the market over three years

Down 35% over the three years to Nov 9 while the S&P 500 rose 80%; up 14% since Nov 5.

The reasons, from its filings, with the timeline, for Pro members.

Key facts on IMCR

Key facts on IMCR
Since its 2024 high	Down 58% while sales grew 60%
Latest filing	8-K, Nov 6 Reported its quarterly results

1 more reason behind IMCR's 2, free with an account →1 more reason behind IMCR's 2, for Pro members.

IMCR in the news

Fri Nov 6Immunocore reported $102.2 million of quarterly revenue and a loss of $0.28 a share SEC, 9:00 AM ET IMCR closed +9.1% that day.

What's next

Tue Nov 17: UBS Global Biopharma Conference 2026Investor conference · date confirmed.

Expected to report Wed Feb 24, before the open

After its last 4 reports it closed +3.7% on average, higher 3 of 4 times.

1 more date ahead: the conference, for Pro members.

Cash$901M in cash. One of the last four quarters brought cash in while the others used it.On Sep 30

IMCR catalysts

Coming up

3 more coming up, with sizes and sources, for Pro members.

What's next for IMCR, and how long its cash lasts

Next step the company has named

2026“The Company expects to present clinical data for brenetafusp from the ovarian and lung cohorts in the Phase 1/2 trial at a medical conference later this year.”Trial data · SEC filing · Nov 6

What it means: the first look at a trial’s main results, as the company reports them.

Lead program: Brenetafusp · Advanced Melanoma · Phase 3
Its trial: PRISM-MEL-301Phase 3 · Recruiting · 680 people · main data estimated Oct 16, 2027 · NCT06112314

5 more trials, 1 with data due this year, 2 more milestones and 34 filings, for Pro members.

Cash runway Sep 30 balance sheet

$901M in cash

One of the last four quarters brought cash in while the others used it, so an average says little about the next.

What it means: a runway is counted only when each of the last four quarters used cash.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: the amounts, and the share count against a year ago.

Insiders

Chief HR Officer Tina Amber St Leger sold 1,000 shares on Feb 18. 3 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Bahija Jallal buys or sells

For Pro members: every trade, and Bahija Jallal’s 5 filings and quotes.

Get an alert when IMCR files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why IMCR scores 2

Below Averagefor quality, not price, 3 of 14 chart checks firingWhat the Quality Score means

+3Chart checks 3 of 14 firing right now, one point each
+1Growth sales up 21% on the year, gross margin down 0.4 points, from Massive's market dataSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.

Cash flow subtracts-1 when free cash flow over the last four quarters is negative.
News subtracts

No effect today: Long-term trend, Run-up, Size, Profit, Dilution, Volatility, and Persistence.

What every line is worth, and the reason behind it, on IMCR and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 11:29 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when IMCR's Quality Score turns up

A free account. No card.

How IMCR ranks in Biotech

IMCR is #115 of 281 by Quality Score.

How IMCR ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	IDYAIDEAYA Biosciences		Open for its score
	IKTInhibikase Therapeutics		Open for its score
	IMMXImmix Biopharma		Open for its score
	IMNMImmunome		Open for its score
115	IMCRImmunocore	3/14	2

When does IMCR report earnings, and what happens after?

Expected to report Wed Feb 24, before the open (in 106 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What IMCR reported on Nov 6, 2026

The quarter

A loss of $0.28 a share.

“The increase in net product sales was due to continued growth in the United States, Europe and international regions.”

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

IMCR's results filing gives no sales by line in a table we read. Its annual report gives the year's, in About.

The outlook

No outlook figures read from this release.

In the company's words

“This increase was primarily due to advancement of our clinical programs, including our three Phase 3 trials.”

From its results filing (SEC filing · Nov 6)

The numbers

Market value: $1.5B; today

No analyst estimates on Breakaway: every figure here is filed.

The whole report on IMCR: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

+6.5%+3.6%+9.1%

May 6Aug 6Nov 6

Reported	When	Gap	Reaction	5 days
Nov 6, 2026Before open	Before open	+5.5%	+9.1%	not yet
Aug 6, 2026Before open	Before open	-1.4%	+3.6%	+4.4%
May 6, 2026Before open	Before open	+3.4%	+6.5%	+1.6%

IMCR closed higher after 3 of its last 4 reports.

All 4 reports, and IMCR's Quality Score going into each

IMCR has 3 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on IMCR, and all 14 on every stock.Get in free →

IMCR RSI today: 57.4, above its 50-day and 200-day averages

Not scored

RSI 57.4, MACD above signal, above both averages. Not scored.13 readings

The deep dive on IMCR

What it does and how it makes money4 findingsAn operating loss of $45.4M in fiscal 2025, on $400M of sales.Annual report, filed Feb 25, 2026
Where it stands2 findingsFor Pro members2 findings on where IMCR stands: its cash, debt, and share count, for Pro members
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades IMCR, for Pro members

7 more findings on IMCR, each with its source, for Pro members.

IMCR share count over time

2% more shares than a year earlier.

Weighted shares, quarter to Sep 30, 2026, both from one filing

Shares of IMCR outstanding, as filed
Shares outstanding	As of
51.7M	Oct 31, 2026
51.5M	Jul 31, 2026
50.9M	Apr 30, 2026
50.7M	Jan 31, 2026

Offerings, shelves, and splits of IMCR, from its filings
From its filings	Filed
Registered shares for a later sale (S-3ASR)	Mar 21, 2024

IMCR's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Bahija JallalChief Executive Officer · 1 trade
David M. BermanHead of R&d · 7 trades
John GollSVP, Finance & CAO · 1 trade
Tina Amber St LegerChief HR Officer · 1 trade

See insider trades by person

About Immunocore Holdings

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

524 employeesOxfordshireimmunocore.com

What Immunocore Holdings says it competes with

“The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies and intense competition.”

From its annual report, SEC filing · Feb 25, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on IMCR and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn IMCR's score around: 7 things
2 more filings explained, a plain line each
Real-⁠time prices, no delay

See IMCR's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: IMCR's Quality Score is 2 (Below Average), #115 of 281 in Biotech.

What does IMCR's Quality Score say?

IMCR scores 2 today, which Breakaway calls Below Average. It is #115 of 281 in Biotech by Quality Score, with 3 of 14 chart checks firing. Up 14% from Nov 5 to Nov 10. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is IMCR's Quality Score?

IMCR scores 2 today, which Breakaway calls Below Average (0 to 5). That is #115 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind IMCR's 2.

When does IMCR report earnings?

Expected to report Wed Feb 24, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. IMCR closed higher after 3 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.